HDAC9 and Hepatic fibrosis: Regarding liver or hepatic fibrosis, Özel et al. published a study in 2021 regarding the in vitro effects of vorinostat (an FDA-approved pan-HDAC inhibitor, 16, Figure 3) in LX2 cells isolated from human hepatic stellate cells (HSCs) [43].